Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 142   

Articles published

NVS 92.67 +0.72 (0.78%)
price chart
Novartis Sells Its Low-Margin Influenza Vaccine Business
Novartis AG (ADR) (NVS) announced before US markets opened for Monday's trading session that it has agreed to sell its �global influenza vaccine business,� including the company's pipeline development products, to Australia-based biotech CSL Ltd.
Related articles »  
Watch List Highlights - Novartis AG (ADR) (NYSE:NVS), Receptos Inc (NASDAQ ...
Novartis AG (ADR) (NYSE:NVS), the global pharmaceuticals company posted Q3 earnings and sales that topped estimates.
Stocks in Focus- Bristol-Myers Squibb Co (NYSE:BMY), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) declared that the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has mutually voted in favor of admiring AIN457 a selective interleukin-17A inhibitor for the treatment of moderate to severe plaque psoriasis in ...
Related articles »  
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Eye Catching Stocks: EXCO Resources Inc (NYSE:XCO), Novartis AG (ADR ...
Novartis AG (ADR) (NYSE:NVS) presents data at EADV showing reliable efficiency of AIN457 in clearing skin of psoriasis patients (NVS) : new investigation of AIN457 (secukinumab) Phase III studies explains that treatment with secukinumab 300 mg resulted ...
Related articles »  
Novartis Announces Positive Phase-III Results For Secukinumab
Novartis AG (ADR) (NVS) announced today that its experimental drug AIN457 (Secukinumab) met its primary and secondary end points in two late-stage trials called MEASURE 1 and MEASURE-2.
Related articles »  
FDA Advisory Committee Votes In Favor Of Novartis' IL-17 Inhibitor
Novartis AG (ADR) (NVS) announced yesterday that the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA has unanimously recommended the use of Novartis' AIN457 in adults who are suffering from moderate-to-severe plaque psoriasis.
Related articles »  
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Related articles »  
Volatile Movements - Novartis AG (ADR) (NYSE:NVS), Garmin Ltd. (NASDAQ ...
Novartis AG (ADR) (NYSE:NVS) offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical ...
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...
Related articles »